Skip to content

InVivo Biosystems vs Parse Biosciences

InVivo Biosystems logo

InVivo Biosystems

Fueling discovery gene by gene

59 employees · est. 2011 · Eugene, United States

VS
Parse Biosciences logo

Parse Biosciences

Scalable Single Cell Sequencing Without the Instrument

148 employees · est. 2018 · Seattle, United States

InVivo Biosystems is the older company (2011 vs 2018).

Side-by-Side Comparison

InVivo Biosystems Parse Biosciences
Founded
2011 older 2018
Headquarters
Eugene, United States Seattle, United States
Employees
59 148
Industry
Biotechnology, Health and Wellness, Life Sciences Biotechnology, Life Sciences, Clean Energy
Funding Stage
Venture round Acquired
Total Funding
$12.80M $299.70M
Funding Rounds
7 6
Services
Not tracked yet Single cell sequencing services, Whole transcriptome analysis, Data analytics for sequencing, Immune profiling (TCR and BCR), Automation of sequencing workflows
Target Customers
Not tracked yet Research laboratories, Biotech companies, Academic researchers, Biomedical scientists, Immunologists
Taxonomy
CRISPR Genome EditingBiomedical ResearchDrug DiscoveryGenetic ModificationDisease ModelingHuman Health +9 Single Cell SequencingCombinatorial CDNA BarcodingBiotechnology StartupCancer ResearchTissue RepairStem Cell Therapy +9
Website
invivobiosystems.com parsebiosciences.com
InVivo Biosystems logo

About InVivo Biosystems

InVivo Biosystems is a leading player in the biotechnology industry, aiming to accelerate deep in-vivo insights into human biology. Specializing in CRISPR genome editing, the company creates custom genome-edited C. elegans and zebrafish models, facilitating studies on aging, developmental processes,...

Parse Biosciences logo

About Parse Biosciences

Parse Biosciences, founded in 2018 and headquartered in the United States, is a dynamic player in the Biotechnology and Life Sciences sectors. With a compelling slogan—"Scalable Single Cell Sequencing Without the Instrument"—the company is focused on revolutionizing single cell sequencing. Its innov...

Also comparing in this category

Comparing more than these two?

Get InVivo Biosystems, Parse Biosciences and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does InVivo Biosystems compare?

A PDF of InVivo Biosystems and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

InVivo Biosystems was founded in 2011, based in Eugene, United States, with 59 employees. InVivo Biosystems is a leading player in the biotechnology industry, aiming to accelerate deep in-vivo insights into human biology. Specializing in CRISPR genome editing, the company creates custom ge. Parse Biosciences was founded in 2018, based in Seattle, United States, with 148 employees. Parse Biosciences, founded in 2018 and headquartered in the United States, is a dynamic player in the Biotechnology and Life Sciences sectors. With a compelling slogan—"Scalable Single Cell Sequencing.
InVivo Biosystems has raised $12.80M and Parse Biosciences $299.70M. Latest stage: InVivo Biosystems Venture round, Parse Biosciences Acquired.
Both work in Biotechnology and Life Sciences and list cancer research among their focus areas.

Compare InVivo Biosystems with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at InVivo Biosystems on 12 Sep 2024, and Parse Biosciences on 8 Nov 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout